Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016

Details for Mechanism ID: 16736
Country/Region: Botswana
Year: 2016
Main Partner: International Federation of Red Cross and Red Crescent Societies
Main Partner Program: Botswana
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $100,000 Additional Pipeline Funding: $300,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Treatment: ARV Drugs (HTXD) $100,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
PMTCT_ART New on ART 2017 16
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 3
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 3
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 97
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 204
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 9
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 10
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 320
TX_CURR Aggregated Age/Sex: <15 Female 2017 9
TX_CURR Aggregated Age/Sex: <15 Male 2017 10
TX_CURR Aggregated Age/Sex: 15+ Female 2017 97
TX_CURR Aggregated Age/Sex: 15+ Male 2017 204
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 320
TX_CURR Sum of Aggregated Age/Sex <15 2017 19
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 301
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 320
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 2
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 2
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 18
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 38
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 60
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 60
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 320
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 320
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 8
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 9
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 88
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 183
TX_PVLS Numerator: Indication: Routine 2017 259
TX_PVLS Numerator: Indication: Targeted 2017 29
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 9
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 10
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 97
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 204
TX_PVLS_den Denominator: Indication: Routine 2017 288
TX_PVLS_den Denominator: Indication: Targeted 2017 32
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 15
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 32
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 50
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 60
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 18
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 38